Next-Generation Breast Cancer Diagnostic and Screening Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Products is the fastest growing sector, North America is the largest market

The Global Next-Generation Breast Cancer Diagnostic and Screening Market is poised for substantial growth, projected to increase from USD 4.81 Billion in 2025 to USD 8.84 Billion by 2031, at a CAGR of 10.68%. This market includes advanced solutions like genomic profiling assays, liquid biopsy platforms, and AI-enhanced imaging systems, all designed to offer superior precision in detecting malignancies compared to traditional methods. Market expansion is primarily fueled by the rising global prevalence of breast cancer and a significant shift towards personalized medicine, which demands molecular-level tumor analysis for effective treatment strategies. For instance, the American Cancer Society anticipated approximately 316,950 women in the United States would be diagnosed with invasive breast cancer in 2025, highlighting the critical demand for these precise diagnostic capabilities.

Market Drivers

A primary market driver is the integration of Artificial Intelligence (AI) in diagnostic imaging, which fundamentally enhances screening protocols by improving sensitivity and optimizing radiologist workflows. AI algorithms effectively identify subtle malignancies and mitigate false negatives in dense breast tissue, thereby significantly boosting diagnostic accuracy; a real-world study showed AI-supported screening increased breast cancer detection rates by 17.6%, achieving 6.7 detections per 1,000 women. Simultaneously, the increasing adoption of liquid biopsy and non-invasive diagnostics is transforming personalized medicine and treatment monitoring. These genomic tools enable early detection of circulating tumor DNA, allowing clinicians to dynamically tailor therapies and detect recurrence sooner than traditional imaging, proving vital as global breast cancer cases are projected to rise to 3.2 million annually by 2050.

Market Challenges

The high implementation costs associated with advanced technologies represent a significant challenge to the growth of the Global Next-Generation Breast Cancer Diagnostic and Screening Market. Integrating genomic profiling assays and AI-driven imaging systems demands substantial capital investment and specialized infrastructure, creating a financial barrier that many healthcare facilities, particularly in price-sensitive regions with stretched budgets, find difficult to overcome. Furthermore, existing reimbursement frameworks often inadequately cover the premium pricing of these innovative solutions, compelling providers to opt for less expensive, traditional methods despite the potential for enhanced detection. This economic strain extends to national health systems, where the substantial financial burden of breast cancer, projected to cost the UK economy between £3.2 billion and £3.5 billion annually in 2025, often prioritizes strict cost-containment measures over the adoption of premium diagnostic technologies, consequently limiting market scaling and widespread implementation.

Market Trends

The implementation of Automated Breast Ultrasound (ABUS) for screening dense breast tissue is becoming a key diagnostic standard, effectively addressing the limitations of conventional mammography, which often struggles with such tissue density. This volumetric 3D ultrasound technology ensures consistent, reproducible screening by de-linking image acquisition from operator skill, crucial for reducing false negatives and detecting interval cancers missed by X-ray systems; the Invenia ABUS Premium system, for example, detected 35.7% more cancers when used with mammography. Concurrently, the rising utilization of Contrast-Enhanced Mammography (CEM) offers a highly sensitive and cost-effective alternative to Magnetic Resonance Imaging (MRI) for high-risk assessments and inconclusive diagnoses. CEM utilizes iodinated contrast agents to visualize tumor neovascularization, providing superior clarity for lesion detection without the considerable operational costs or accessibility constraints of MRI protocols, with clinical studies indicating it successfully depicted 90% of breast cancers compared to just 10% with low-energy mammograms.

Key Market Players

• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Hologic, Inc.
• Siemens Healthineers AG
• Danaher Corporation
• Becton, Dickinson and Company
• Agilent Technologies, Inc.
• Sysmex Corporation

Report Scope

In this report, the Global Next-Generation Breast Cancer Diagnostic and Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next-Generation Breast Cancer Diagnostic and Screening Market, by Technology:

• Real-Time PCR
• Immunohistochemistry (IHC)
• Next-Generation Sequencing (NGS)
• Fluorescence In-Situ Hybridization (FISH)
• Others

Next-Generation Breast Cancer Diagnostic and Screening Market, by Biomarker:

• BRCA1/2
• ER/PR Receptors
• HER-2
• Others

Next-Generation Breast Cancer Diagnostic and Screening Market, by Cancer Sub-Type:

• Luminal A
• Luminal B
• Triple Negative/Basal Like
• Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched

Next-Generation Breast Cancer Diagnostic and Screening Market, by Offering:

• Products
• Services

Next-Generation Breast Cancer Diagnostic and Screening Market, by End User:

• Hospitals and Clinics
• Diagnostic Centers and Reference Labs
• Academic & Research Institutes

Next-Generation Breast Cancer Diagnostic and Screening Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next-Generation Breast Cancer Diagnostic and Screening Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.